Standalone & Consolidated Financial Results, Limited Review Report for December 31, 2016
Zydus Wellness Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Consolidated Financial Results for the period ended December 31, 20163. Standalone Limited Review for the period ended December 31, 20164. Consolidated Limited Review for the period ended December 31, 2016 Change in time of Analyst / Institutional Investors' meet
Zydus Wellness Ltd has informed BSE regarding "Change in the time of Analyst / Institutional Investors' meet". Zydus adds muscle with US buy
String of brand buying in India to give it more diversified portfolio Schedule of Analyst / Institutional Investors' meet
Zydus Wellness Ltd has informed BSE regarding "Schedule of Analyst / Institutional Investors' meet". Zydus gets USFDA nod for chemotherapy drug
The drug will be produced at the group's manufacturing facility in Ahmedabad Board Meeting Intimation for Results & Closure of Trading Window
Zydus Wellness Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on January 30, 2017 to consider apart from other agenda items to approve the unaudited financial results for the quarter / nine months ended on December 31, 2016.Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will... Shareholding for the Period Ended December 31, 2016
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Zydus Wellness Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Zydus acquires six brands from US pharma player MSD
Recalls over 16,000 bottles of depressive disorder drug in US Appointment of Additional Independent Director
Zydus Wellness Ltd has informed BSE that Mr. Kulin Lalbhai is appointed as an Additional Independent Director of the Company for a period of five consecutive years, subject to approval of the members at the ensuing Annual General Meeting.